Use of soluble CD164 in inflammatory and/or autoimmune disorders
View Patent ↗The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of human CD164, in particular for treating inflammatory and/or autoimmune disorders.
1. A method of reducing serum transaminase, IFN-γ and IL-6 levels in an individual having fulminant liver hepatitis comprising the administration of a composition comprising a soluble protein comprising SEQ ID NO: 1 to an individual having fulminant liver hepatitis in an amount sufficient to reduce serum transaminase, IFN-γ and IL-6 levels in said individual.
2. The method according to claim 1 , wherein said soluble protein is chosen from:
a) SEQ ID NO: 1; or
b) SEQ ID NO: 1 fused to the signal sequence of human CD164.
3. The method according to claim 1 , wherein said soluble protein is glycosylated.
4. The method according to claim 3 , wherein said soluble protein is glycosylated at any of the positions as set forth in SEQ ID NO: 1.
5. The method according to claim 1 , wherein said soluble protein is phosphorylated.
6. The method according to claim 5 , wherein said soluble protein is phosphorylated at any of the positions as set forth in SEQ ID NO: 1.
7. The method according to claim 1 , wherein said soluble protein is myristoylated.
8. The method according to claim 7 , wherein said soluble protein is myristoylated at any of the positions as set forth in SEQ ID NO: 1.
9. The method according to claim 1 , wherein said soluble protein is a soluble fusion protein.
10. The method according to claim 9 , wherein said soluble fusion protein comprises a signal sequence.
11. The method according to claim 9 , wherein said soluble fusion protein contains a Histidine tag.
12. The method according to claim 11 , wherein said soluble fusion protein is SEQ ID NO: 2.
13. The method according to claim 9 , wherein said soluble fusion protein comprises an Fc region of an immunoglobulin.